Core Viewpoint - The national drug supervision management conference emphasized key tasks for achieving a good start in the 14th Five-Year Plan by 2026, focusing on drug safety, industry development, legal regulation, and modernization of drug supervision [1] Group 1: Drug Safety - The conference highlighted the need to ensure high-level drug safety by improving the drug safety responsibility system and enhancing the supervision of clinical trials [1] - There will be increased inspections and sampling for key varieties, particularly those selected in centralized procurement [1] - The conference called for strengthening the regulation of online sales and maintaining a strict bottom line for drug safety [1] Group 2: Industry Development - Support for the pharmaceutical industry will be enhanced through comprehensive reforms in drug regulation, with a focus on early intervention and tailored guidance for key products [1] - The conference aims to promote innovation in drug research and development, as well as the development of traditional Chinese medicine and high-level self-reliance in medical devices [1] - There is an emphasis on fostering the growth of the beautiful economy within the pharmaceutical sector [1] Group 3: Legal Regulation - Continuous improvement of the legal and regulatory framework for drug supervision is a priority, including enhancing the authority and credibility of administrative law enforcement [1] - The conference plans to increase legal awareness among enterprises and grassroots organizations to solidify the legal foundation of drug supervision [1] Group 4: Modernization of Drug Supervision - The conference aims to develop a high-quality "14th Five-Year" drug planning and promote the integration of national drug supervision [1] - There will be a focus on building a capable regulatory workforce and enhancing technological support for drug supervision [1] - The conference also emphasizes the importance of participating in global drug safety governance to elevate China's international influence in drug regulation [1]

Core Viewpoint - The "14th Five-Year Plan" period marks a critical phase for the pharmaceutical regulatory sector in Shaanxi Province, emphasizing the importance of political leadership, regulatory rigor, and innovation to ensure drug safety and promote the development of the pharmaceutical industry [1] Group 1: Leadership and Governance - The Shaanxi Provincial Drug Administration has integrated the leadership of the Communist Party into all aspects of drug regulation, aiming to build a trustworthy regulatory team [2] - The agency has implemented a standardized construction of party branches and created 35 party brand initiatives to enhance regulatory effectiveness [3] Group 2: Regulatory Framework and Risk Management - The agency has established a comprehensive drug safety protection system, focusing on risk prevention and control, and has developed a risk assessment mechanism to proactively manage potential issues [6][7] - A total of 4,839 inspections of drug production and 442,303 inspections of drug distribution and use have been conducted, leading to the identification and rectification of numerous violations [8] Group 3: Technological Innovation and Digital Transformation - The Shaanxi Provincial Drug Administration is advancing a smart regulatory system, including the establishment of a drug safety regulatory platform and a drug regulatory big data center, which has processed over 21.7 million applications [10][11] - The drug safety risk management system has identified 23,614 safety risk signals, providing a robust technical foundation for high-quality regulatory oversight [12] Group 4: Industry Support and Development - The agency has optimized the review and approval processes for innovative drugs, significantly reducing approval times and supporting the development of 77 innovative drug specifications [14][15] - Policies have been implemented to encourage the quality and efficacy consistency of generic drugs, with a total of 52.7 million yuan in rewards distributed to relevant enterprises [16] Group 5: Cultural and Educational Initiatives - The agency has focused on enhancing the cultural atmosphere of integrity within the pharmaceutical sector, addressing 288 issues and implementing 397 corrective measures over five years [5] - Educational programs and training sessions have been conducted to improve the capabilities of regulatory personnel, including 230 participants in emergency management training [7]

Group 1: Market Regulation Achievements - Since the beginning of the 14th Five-Year Plan, the national market regulatory authorities have improved the supervision system for enterprise-related fees, continuously reducing operational costs for businesses. The number of new enterprises increased by 19.99 million, and individual businesses increased by 33.94 million [1][2] - The introduction of the "Fair Competition Review Regulations" has established rigid institutional constraints against issues such as "malicious competition" in investment promotion and administrative monopolies. A total of 4,218 policies that hindered the flow of factors were abolished, and 239 administrative monopoly cases were investigated [1][2] Group 2: Consumer Protection and Efficiency - During the 14th Five-Year Plan, market regulatory authorities handled 89.03 million complaints, recovering economic losses of 21.71 billion yuan for consumers. Consumer associations processed 5.75 million complaints, recovering 5.78 billion yuan [2] - The time required to open a restaurant has been reduced from 37 days to 15 days, and the number of documents required for business information changes has been streamlined from 23 to 6 [2] Group 3: Platform Economy Regulation - The platform economy is undergoing a critical transformation, with the integration of digital technology across industries leading to new growth points but also risks such as algorithm abuse and disorderly competition. Regulatory authorities are balancing innovation encouragement with development regulation [4][5] - Regulatory actions have led to the removal of 4.54 million illegal product listings and the suspension of services for 58,000 online stores. Major cases in the live-streaming e-commerce sector have been addressed [5] Group 4: Pharmaceutical Industry Developments - China's pharmaceutical industry ranks second globally, with 204 innovative drugs and 265 innovative medical devices approved since the beginning of the 14th Five-Year Plan. The number of innovative drugs in development accounts for about 30% of the global total [7][8] - The National Medical Products Administration has implemented dynamic supervision covering the entire drug lifecycle, focusing on key areas such as online sales and clinical trial management [7][8]